Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.

Reuters could not immediately verify the report.

(Reporting by Ananya Palyekar in Bengaluru; Editing by Alan Barona)